Solara is executing a profound strategic pivot, shifting decisively away from lower-margin, non-regulated markets to focus on higher-value, regulated international markets. This strategic re-orientation has already seen regulated markets contribute a considerable 76% to the corporate’s complete enterprise. Concurrently, Solara is actively decreasing its reliance on the plain Ibuprofen drug, as an alternative prioritizing enlargement in value-added Ibuprofen derivatives and a diversified portfolio of non-Ibuprofen merchandise.